These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10565690)

  • 1. Epirubicin approved for breast cancer treatment.
    Miller JL
    Am J Health Syst Pharm; 1999 Nov; 56(21):2177. PubMed ID: 10565690
    [No Abstract]   [Full Text] [Related]  

  • 2. Epirubicin as adjuvant therapy for breast cancer.
    Suh C
    Cancer Pract; 2001; 9(2):104-6. PubMed ID: 11879287
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current status of epirubicin in the treatment of breast neoplasm].
    Jiang ZF; Song SC
    Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):193-5. PubMed ID: 15949413
    [No Abstract]   [Full Text] [Related]  

  • 4. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epirubicin for adjuvant therapy in node-positive breast cancer.
    Med Lett Drugs Ther; 2000 Feb; 42(1071):12-3. PubMed ID: 10725968
    [No Abstract]   [Full Text] [Related]  

  • 6. Epirubicin hydrochloride.
    Dolbey C
    Clin J Oncol Nurs; 2002; 6(4):247-8. PubMed ID: 12087624
    [No Abstract]   [Full Text] [Related]  

  • 7. Epirubicin as adjuvant therapy in breast cancer.
    Earl H; Iddawela M
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin for breast cancer during pregnancy: a case report.
    Eedarapalli P; Biswas N; Coleman M
    J Reprod Med; 2007 Aug; 52(8):730-2. PubMed ID: 17879836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polychemotherapy versus monotherapy in metastatic breast carcinoma].
    Tanner J; Dunst J
    Strahlenther Onkol; 1999 Sep; 175(9):471. PubMed ID: 10518983
    [No Abstract]   [Full Text] [Related]  

  • 10. Sino-atrial block during anesthesia in a patient with breast cancer being treated with the anticancer drug epirubicin.
    Okamoto T; Ogata J; Minami K
    Anesth Analg; 2003 Jul; 97(1):19-20, table of contents. PubMed ID: 12818936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study.
    Fountzilas G; Nicolaides C; Aravantinos G; Skarlos D; Kosmidis P; Papakostas P; Stathopoulos GP; Kontostolis E; Bafaloukos D; Pavlidis N
    Oncology; 1998; 55(6):508-12. PubMed ID: 9778614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance.
    Press MF; Gordon MA; Slamon DJ
    J Clin Oncol; 2012 Feb; 30(4):357-61. PubMed ID: 22203766
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
    Ventura GJ
    J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
    [No Abstract]   [Full Text] [Related]  

  • 14. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
    Findlay BP; Walker-Dilks C
    Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anthracycline induced cardiomyopathy in 51-years old women with breast cancer].
    Biskup P; Wozakowska-Kapłon B; Góźdź S
    Pol Arch Med Wewn; 2006 Jun; 115(6):551-8. PubMed ID: 17263227
    [No Abstract]   [Full Text] [Related]  

  • 16. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
    Ormrod D; Holm K; Goa K; Spencer C
    Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
    Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
    Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment.
    Du J; Zhang Y; Ming J; Liu J; Zhong L; Liang Q; Fan L; Jiang J
    World J Surg Oncol; 2016 Jun; 14(1):164. PubMed ID: 27335011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.
    Coukell AJ; Faulds D
    Drugs; 1997 Mar; 53(3):453-82. PubMed ID: 9074845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.